Azacitidine followed by R-GDP in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma: preliminary results from a multicenter, phase II study

Background: Epigenetic priming prior to chemotherapy represents a promising treatment strategy for refractory or relapsed diffuse large B-cell lymphoma (R/R DLBCL). We conducted a phase II trial to evaluate the efficacy and safety of azacitidine in combination with R-GDP (rituximab/gemcitabine/dexam...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Dong Hyun Kim, Jee Hyun Kong, Junshik Hong, Ja Min Byun, Dong-Yeop Shin, Youngil Koh, Inho Kim, Jinny Park, Young Rok Do, Jeong-A Kim, Won Seog Kim, Ho-Jin Shin, Sung-Soo Yoon
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	SAGE Publishing 2025-07-01
Serie:	Therapeutic Advances in Hematology
Länkar:	https://doi.org/10.1177/20406207251349361
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!